Page last updated: 2024-12-08
rotundifolone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
rotundifolone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 442497 |
| CHEBI ID | 8900 |
| SCHEMBL ID | 2317471 |
| MeSH ID | M0442088 |
Synonyms (26)
| Synonym |
|---|
| piperitenone oxide |
| 3564-96-3 |
| rotundifolone |
| C09896 |
| lippione |
| (1s,6s)-6-methyl-3-propan-2-ylidene-7-oxabicyclo[4.1.0]heptan-2-one |
| 6fr5iod112 , |
| piperitenone oxide, (+-)- |
| cis-piperitenone epoxide |
| 7-oxabicyclo(4.1.0)heptan-2-one, 6-methyl-3-(1-methylethylidene)-, (1s)- |
| unii-6fr5iod112 |
| (+-)-rotundifolone |
| piperitenone oxide [fhfi] |
| fema no. 4199 |
| 7-oxabicyclo(4.1.0)heptan-2-one, 6-methyl-3-(1-methylethylidene)-, (1s,6s)- |
| (+-)-piperitenone oxide |
| (+)-piperitenone oxide |
| piperitenone oxide, (+)- |
| (+)-rotundifolone |
| SCHEMBL2317471 |
| CHEBI:8900 |
| Q27108176 |
| DTXSID301317536 |
| HY-134013 |
| CS-0136507 |
| AKOS040753565 |
Research Excerpts
Actions
| Excerpt | Reference | Relevance |
|---|---|---|
| "Rotundifolone elicits an increase in the current density of BK(Ca) channels and causes a shift in the steady-state inactivation relationship for Ca(v) type-L towards more hyperpolarized membrane potentials." | ( Rotundifolone-induced relaxation is mediated by BK(Ca) channel activation and Ca(v) channel inactivation. Albuquerque, JG; Araújo, DA; Araújo, IG; Barbosa-Filho, JM; Cavalcante, KV; Correia, NA; Cruz, JS; De Medeiros, IA; Dias, KL; Nunes, XP; Porto, DL; Silva, DF; Veras, RC, 2011) | 2.53 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| oxacycle | Any organic heterocyclic compound containing at least one ring oxygen atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.15) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||